Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human phase 1 clinical trial of CpG STAT3siRNA gene therapy in B-cell non-Hodgkin lymphoma patients

Trial Profile

A first-in-human phase 1 clinical trial of CpG STAT3siRNA gene therapy in B-cell non-Hodgkin lymphoma patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DUET 01 (Primary)
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man

Most Recent Events

  • 24 May 2021 According to a Scopus BioPharma media release, the company has received the approval of an investigational new drug application (IND) by the United States Food and Drug Administration (FDA).
  • 26 Apr 2021 According to a Scopus BioPharma media release, the company announced the submission of an investigational new drug application to the United States Food and Drug Administration for its immuno-oncology RNA therapy for the treatment of multiple cancers.
  • 19 Jan 2021 According to a Scopus BioPharma media release, clinical lot manufacturing has been completed fulfilling the requirements of this study and this will enable finalization of the investigational new drug ("IND") package for submission to the United States Food and Drug Administration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top